ANL - Adlai Nortye Limited Short-Term Debt to Capital

Official company branding of Adlai Nortye Ltd. (ANL)

This price chart on GURU.Markets for Adlai Nortye Ltd. (ANL) demonstrates the 0.07 metric. Adlai Nortye Ltd. is a biopharmaceutical firm developing oncology drugs with global sales potential and high margins following patent approval. The company minimizes risks by distributing its research centers across Europe, China, and the US. Supply chain efficiency is ensured through flexible management of regional hubs and precise raw material procurement planning.

ANL - adlainortye.com Current Liabilities to Capital over the range 02/21/2024 - 11/01/2026

Financial and market metric breakdowns for Adlai Nortye Limited (ANL)

- stock value and consensus price forecast:
Price Chart Adlai Nortye Ltd.|ANL - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Adlai Nortye Ltd|ANL - Real Price to Acquire Entire Company
- book capitalization information:
Book Value per Share Adlai Nortye|ANL - Total Stockholders' Equity|Market Value to Book Value Ratio adlainortye.com|ANL - Aggregate Asset Value
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Adlai Nortye Ltd.|ANL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Adlai Nortye Ltd.|ANL - Company Total Debt|Debt to Book Value Adlai Nortye Ltd|ANL - Company Long-Term Debts|Company Short-Term Debt Adlai Nortye|Quick Ratio adlainortye.com
- earnings and market ratios statistics:
ANL - Company Net Income
Fundamental company analysis:Adlai Nortye ANL
Product sample of Adlai Nortye Limited

For Adlai Nortye Ltd. (ANL), which maneuvers between US and PRC regulators, the structure of short-term liabilities relative to capital serves as an indicator of financial resilience to geopolitical shocks. This metric measures the proportion of loans with a maturity of over one year relative to equity, allowing for an assessment of the business's ability to withstand peak loads and balance excessive caution with the efficient use of borrowed funds.

Analysis of competing companies

Short-Term Debt to Equity BeiGene Corp (ONC)|Halozyme Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital RVMD (Revolution Medicines)|AAPG - Short-Term Debt to Equity Ratio|CG Oncology - Short-Term Debt to Capital|Current Liabilities to Capital UroGen Pharma Ltd|Bicara Bio (BCAX) - Short-Term Debt to Equity|Personalis Genomics - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ERAS|DCTH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital YMAB|Short-Term Debt to Equity Ratio Aura Biosciences Inc AURA|Candel Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Accuray, Inc. ARAY|SLS - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ACTU (actuatetherapeutics.com)|CTOR: Short-Term Debt to Capital|Current Liabilities to Capital TuHURA Biosciences (HURA)|TARA (Protara) - Short-Term Debt to Capital|Short-Term Debt to Capital Fate Pharma|Short-Term Debt to Capital WHWK|tscan.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Champions Oncology, Inc. CSBR|XBiotech Inc - Short-Term Debt to Equity|CEL-SCI Corp - Short-Term Debt to Capital|OSTX - Short-Term Debt to Capital|RADX: Short-Term Debt to Capital|ARTV - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio VERU|TPST: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Xilio Therapeutics, Inc. (XLO)|renovarobio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Mural Oncology MURA|Kairos Pharma Limited (KAPA) - Current Liabilities to Capital|OKUR - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital GDTC (CytoMed Therapeutics)|CRIS (curis.com) - Short-Term Debt to Equity Ratio|APLM: Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio THAR|Current Liabilities to Capital Advanced Biomed Corp ADVB|Short-Term Debt to Capital GNPX|CLDI - Current Liabilities to Capital|Sunshine Biopharma - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital XBIO|SLRX - Short-Term Debt to Equity|PPBT: Short-Term Debt to Equity|AONC (aoncology.com) - Short-Term Debt to Equity Ratio|BGNE: Short-Term Loans to Capital Ratio|CKPT (Checkpoint Therapeutics, Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio ELEV (Elevation Oncology Inc.)|Short-Term Debt to Equity Ratio ICAD (iCAD, Inc.)|Short-Term Debt to Capital Coefficient ikenaoncology.com|Short-Term Debt to Capital NTBL (Notable Labs)|Short-Term Debt to Capital Viracta Therapeutics Inc. VIRX|MOR - Short-Term Debt to Equity|NAYA (NAYA Biosciences Corp) - Short-Term Debt to Capital Ratio|Ascentage Pharma Group (AAPGV) - Short-Term Debt to Equity